Cardiotoxicidade associada aos inibidores de checkpoint: relato de caso
Cardiotoxicity associated with checkpoint inhibitors: report case
DOI:
https://doi.org/10.34119/bjhrv5n6-111Keywords:
Miocardite, imunoterapia, toxidade cardíaca, imunoterápicos, Neoplasias malignasAbstract
Introdução: A evolução da imunoterapia no manejo do paciente oncológico tem se constituído em importante arsenal terapêutico das neoplasias malignas. Entretanto, deve-se conhecer os mecanismos de ação e os principais efeitos colaterais das drogas para adequada monitorização durante o tratamento. Objetivo- Relatar a ocorrência de miocardite após uso de imunoterapia para tratamento de adenocarcinoma de pulmão. Método–Trata-se de um caso clínico, cujas informações foram obtidas mediante análise cuidadosa do prontuário médico, da anamnese e da avaliação dos laudos dos exames complementares submetidos pelo paciente e de revisão de literatura. Conclusão Foi abordado um dos efeitos colaterais mais graves ocasionados por inibidores de checkpoint: a toxidade cardíaca. O diagnóstico precoce permitiu a interrupção da imunoterapia e evitou eventos adversos maiores.
References
Anquetil, C., Salem, J.-E., Lebrun-Vignes, B., Johnson, D. B., Mammen, A. L., Stenzel, W., Léonard-Louis, S., Benveniste, O., Moslehi, J. J., & Allenbach, Y. (2018). Immune checkpoint inhibitor–associated myositis: Expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation, 138(7), 743–745. https://doi.org/10.1161/CIRCULATIONAHA.118.035898
Baik, A. H., Tsai, K. K., Oh, D. Y., & Aras, M. A. (2021). Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clinical Science, 135(5), 703–724. https://doi.org/10.1042/CS20200331
Basso, C. (2022). Myocarditis. New England Journal of Medicine, 387(16), 1488–1500. https://doi.org/10.1056/NEJMra2114478
Bonaca, Marc P., et al. “Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology”. Circulation, vol. 140, no 1, julho de 2019, p. 80–91. DOI.org (Crossref), https://doi.org/10.1161/CIRCULATIONAHA.118.034497
Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary. Journal of Oncology Practice, 14(4), 247–249. https://doi.org/10.1200/JOP.18.00005
Chen, D.-Y., Huang, W.-K., Chien-Chia Wu, V., Chang, W.-C., Chen, J.-S., Chuang, C.-K., & Chu, P.-H. (2020). Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. Journal of the Formosan Medical Association, 119(10), 1461–1475. https://doi.org/10.1016/j.jfma.2019.07.025
Colvin, M. M., Cook, J. L., Chang, P., Francis, G., Hsu, D. T., Kiernan, M. S., Kobashigawa, J. A., Lindenfeld, J., Masri, S. C., Miller, D., O’Connell, J., Rodriguez, E. R., Rosengard, B., Self, S., White-Williams, C., & Zeevi, A. (2015). Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and management: a scientific statement from the american heart association. Circulation, 131(18), 1608–1639. https://doi.org/10.1161/CIR.0000000000000093
Escudier, M., Cautela, J., Malissen, N., Ancedy, Y., Orabona, M., Pinto, J., Monestier, S., Grob, J.-J., Scemama, U., Jacquier, A., Lalevee, N., Barraud, J., Peyrol, M., Laine, M., Bonello, L., Paganelli, F., Cohen, A., Barlesi, F., Ederhy, S., & Thuny, F. (2017). Clinical features, management, and outcomes of immune checkpoint inhibitor–related cardiotoxicity.
Circulation, 136(21), 2085–2087. https://doi.org/10.1161/CIRCULATIONAHA.117.030571
Faje, Alexander T., et al. “High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis Is Associated with Reduced Survival in Patients with Melanoma: Steroids and Hypophysitis Outcomes”. Cancer, vol. 124, no 18, setembro de 2018, p. 3706–14. DOI.org (Crossref), https://doi.org/10.1002/cncr.31629.
Friedrich, Matthias G., et al. “Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper”. Journal of the American College of Cardiology, vol. 53, no 17, abril de 2009, p. 1475–87. DOI.org (Crossref), https://doi.org/10.1016/j.jacc.2009.02.007.
Frigeri, M., Meyer, P., Banfi, C., Giraud, R., Hachulla, A.-L., Spoerl, D., Friedlaender, A., Pugliesi-Rinaldi, A., & Dietrich, P.-Y. (2018). Immune checkpoint inhibitor-associated myocarditis: A new challenge for cardiologists. Canadian Journal of Cardiology, 34(1), 92.e1-92.e3. https://doi.org/10.1016/j.cjca.2017.09.025
Ganatra, S., & Neilan, T. G. (2018). Immune checkpoint inhibitor-associated myocarditis. The Oncologist, 23(8), 879–886. https://doi.org/10.1634/theoncologist.2018-0130
Gianni, M., Dentali, F., Grandi, A. M., Sumner, G., Hiralal, R., & Lonn, E. (2006). Apical ballooning syndrome or takotsubo cardiomyopathy: A systematic review. European Heart Journal, 27(13), 1523–1529. https://doi.org/10.1093/eurheartj/ehl032 ECG 50
Grabie, N., Gotsman, I., DaCosta, R., Pang, H., Stavrakis, G., Butte, M. J., Keir, M. E., Freeman, G. J., Sharpe, A. H., & Lichtman, A. H. (2007). Endothelial programmed death-1 ligand 1 (Pd-l1) regulates cd8 + t-cell–mediated injury in the heart. Circulation, 116(18), 2062–2071. https://doi.org/10.1161/CIRCULATIONAHA.107.709360
Hajjar, L. A., Costa, I. B. S. da S. da, Lopes, M. A. C. Q., Hoff, P. M. G., Diz, M. D. P. E., Fonseca, S. M. R., Bittar, C. S., Rehder, M. H. H. dos S., Rizk, S. I., Almeida, D. R., Fernandes, G. dos S., Beck-da-Silva, L., Campos, C. A. H. de M., Montera, M. W., Alves, S. M. M.,
Fukushima, J. T., Santos, M. V. C. dos, Negrão, C. E., Silva, T. L. F. da, … Kalil, R. (2020).
Diretriz Brasileira de Cardio-oncologia – 2020. Arquivos Brasileiros de Cardiologia, 115(5), 1006–1043. https://doi.org/10.36660/abc.20201006
Ito, F., & Ernstoff, M. S. (Orgs.). (2019). Immune checkpoint inhibitors in cancer. Elsevier.
Jain, V., Bahia, J., Mohebtash, M., & Barac, A. (2017). Cardiovascular complications associated with novel cancer immunotherapies. Current Treatment Options in Cardiovascular Medicine, 19(5), 36. https://doi.org/10.1007/s11936-017-0532-8
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., Becker, J. R., Slosky, D. A., Phillips, E. J., Pilkinton, M. A., Craig-Owens, L., Kola, N., Plautz, G., Reshef, D. S., Deutsch, J. S., … Moslehi, J. J. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of medicine, 375(18), 1749–1755. https://doi.org/10.1056/NEJMoa1609214
Kushnir, I., & Wolf, I. (2017). Nivolumab-induced pericardial tamponade: A case report and discussion. Cardiology, 136(1), 49–51. https://doi.org/10.1159/000447053
Mahmood, S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C., Gupta, D., Kirchberger, M. C., Moslehi, J., Shah, S., Ganatra, S., Thavendiranathan, P., Lawrence, D. P., Groarke, J. D., & Neilan, T. G. (2018). Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology, 71(11), A699. https://doi.org/10.1016/S0735-1097(18)31240-3
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., Klein, O., Hassel, J. C., Sosman, J. A., Guminski, A., Sullivan, R. J., Ribas, A., Carlino, M. S., Davies, M. A., Sandhu, S. K., & Long, G. V. (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28(2), 368–376. https://doi.org/10.1093/annonc/mdw443
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet, 391(10124), 933. https://doi.org/10.1016/S0140-6736(18)30533-6
Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017). Smoldering myocarditis following immune checkpoint blockade. Journal for ImmunoTherapy of Cancer, 5(1), 91. https://doi.org/10.1186/s40425-017-0296-4
Pirozzi, F., Poto, R., Aran, L., Cuomo, A., Galdiero, M. R., Spadaro, G., Abete, P., Bonaduce, D., Marone, G., Tocchetti, C. G., Varricchi, G., & Mercurio, V. (2021). Cardiovascular toxicity of immune checkpoint inhibitors: Clinical risk factors. Current Oncology Reports, 23(2), 13. https://doi.org/10.1007/s11912-020-01002-w
Reddy, N., Moudgil, R., Lopez-Mattei, J. C., Karimzad, K., Mouhayar, E. N., Somaiah, N., Conley, A. P., Patel, S., Giza, D. E., & Iliescu, C. (2017). Progressive and reversible conduction disease with checkpoint inhibitors. Canadian Journal of Cardiology, 33(10), 1335.e13-1335.e15. https://doi.org/10.1016/j.cjca.2017.05.026
Salem, Joe-Elie, et al. “Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis”. New England Journal of Medicine, vol. 380, no 24, junho de 2019, p. 2377–79. DOI.org (Crossref), https://doi.org/10.1056/NEJMc1901677.
Upadhrasta, S., Elias, H., Patel, K., & Zheng, L. (2019). Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Diseases and Translational Medicine, 5(1), 6–14. https://doi.org/10.1016/j.cdtm.2019.02.004
Wainstein, A. J., Calabrich, A., Melo, A. C. de, Buzaid, A. C., Katz, A., Anjos, C. A. dos, Ferreira, C. G., Baldotto, C., Mathias, C. M. de C., Yen, C. T., Sternberg, C., Gomes, E. E., Moura, F., Junior, G. de C., Fernandes, G. dos S., Hoff16, P. M. G., Schmerling, R., Munhoz, R. R., Barroso-Sousa, R., … Lima, V. C. C. de. (2017). Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors. Brazilian Journal of Oncology, 13(43), 1–15. https://www.brazilianjournalofoncology.com.br/details/6/en-US
Walker, L. S. K., & Sansom, D. M. (2011). The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nature Reviews Immunology, 11(12), 852–863. https://doi.org/10.1038/nri3108
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., Rathmell, W. K., Ancell, K. K., Balko, J. M., Bowman, C., Davis, E. J., Chism, D. D., Horn, L., Long, G. V., Carlino, M. S., Johnson, D. B. (2018). Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncology, 4(12), 1721. https://doi.org/10.1001/jamaoncol.2018.3923
Yang, J., Riella, L. V., Chock, S., Liu, T., Zhao, X., Yuan, X., Paterson, A. M., Watanabe, T.,
Vanguri, V., Yagita, H., Azuma, M., Blazar, B. R., Freeman, G. J., Rodig, S. J., Sharpe, A. H.,
